Cancer
Scientists have discovered that the Lewis-Y carbohydrate antigen is expressed on a range of tumors, including squamous cell lung carcinoma, lung adenocarcinoma, ovarian carcinoma, and colorectal adenocarcinoma. Specifically, 42% of squamous cell lung carcinoma, 80% of lung adenocarcinoma, 25% of ovarian carcinoma, and 25% of colorectal adenocarcinoma expressed Lewis-Y. Furthermore,
Cancer research
Research published in the journal Molecular Pharmacology has shed light on the complex interactions between integrins and oncogenes in cancer cells. According to a study conducted by J.C. Puigvert and colleagues at Leiden University, the expression profiles of oncogenes and integrins significantly affect the response to chemotherapeutics, ultimately determining
Cancer research
South Korea's state-run bioscience laboratory, the Korea Research Institute of Bioscience and Biotechnology (KRIBB), has partnered with the pharmaceutical giant Pfizer Inc. to develop new cancer treatment materials. The collaborative project, which will span two years, aims to find candidate materials for liver and stomach cancer treatments. KRIBB
Cancer
Researchers at Baylor College of Medicine have conducted a study to evaluate the chemopreventive effects of three agents, rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib, on mammary tumor development in p53-null mammary epithelium. The study found that rexinoid bexarotene was the most efficacious inhibitor, reducing mammary tumor development by
Cancer
Scientists have developed a novel drug delivery system that targets specific cancer cells using a monoclonal antibody. The system, which uses doxorubicin-loaded, long-circulating liposomes, has shown significant improvement in tumor accumulation and therapeutic effect compared to traditional treatments. Researchers at Northeastern University, led by T. Elbayoumil, conducted a study in
Cancer research
In a groundbreaking study published in Cancer Immunology, Immunotherapy, researchers from the University States have made significant progress in developing a universal and safe cancer immunotherapy using lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene. The study aims to target MUC1 tumor antigen, a common
Cancer research
Scientists at the University of Marburg, Medical Department, have discovered a novel non-viral delivery platform for therapeutic siRNAs, which shows promise in treating cancer. Researchers have developed pegylated siRNA/cationic liposome (slRNA/PEG-LIC) complexes that exhibit favorable pharmacokinetic properties and biodistribution profiles. These complexes accumulate in subcutaneous prostate carcinoma xenografts,
Cancer research
Researchers at The University of Texas at Austin have found that infection with recombinant adenoviruses can significantly alter the pharmacokinetics of chemotherapeutic agents, such as docetaxel, used in cancer treatment. This is concerning because it may cause variability in the efficacy and safety of these treatments. The study, published in
Cancer research
Researchers in Saskatoon, Canada, have made a groundbreaking discovery in cancer gene therapy, detailing the eradication of well-established tumors and induction of long-term antitumor immunity through transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under the control of the human telomerase reverse transcriptase promoter. This innovative
Cancer
Researchers at Ningbo University in the People's Republic of China have discovered a significant synergistic effect when combining docosahexaenoic acid (DHA) and 5-fluorouracil (5-FU) in suppressing the growth of gastric carcinoma cells. This study suggests that DHA enhances the anticancer effect of 5-FU by increasing the early phase
Cancer
Researchers at the University of Cologne in Germany have published a study in the Annals of Surgical Oncology, finding that DAPK (Death-Associated Protein Kinase) methylation in pretreatment biopsies of patients with locally advanced cancer of the esophagus is not a reliable marker for predicting histomorphological regression or prognosis following neoadjuvant
Cancer
In a groundbreaking study published in the journal Cancer Immunology, Immunotherapy, researchers from the University of Kentucky have made a startling discovery about the effects of a homodimerizing antibody on human non-small cell lung cancer cells. Contrary to conventional wisdom, the study found that increasing the concentration of the antibody
